Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Last trade$7.21
Day change-$0.01 (-0.14%)
Day range$6.65 – $7.58
Volume270,943
Market cap$751M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$751.42M
Price / earnings
—
Price / book
2.61×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.92×
Profitability
Earnings per share
-$1.32
Return on assets
-42.58%
Return on equity
-47.65%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.21×
Quick ratio
14.21×
Cash ratio
1.95×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$109.68M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AURA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$10.32M
$17.32M
$6.91M
$5.34M
$5.73M
$5.73M
$5.69M
$5.47M
Research and development
$24.74M
$30.75M
$27.96M
$21.9M
$22.18M
$22.88M
$23.34M
$22.33M
Total operating expenses
$35.06M
$48.07M
$34.87M
$27.24M
$27.91M
$28.61M
$29.04M
$27.81M
Operating income
-$35.06M
-$48.07M
-$34.87M
-$27.24M
-$27.91M
-$28.61M
-$29.04M
-$27.81M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$32.03M
-$45.61M
-$33.67M
-$25.54M
-$26.1M
-$26.97M
-$27.47M
-$25.81M
Income taxes
$38K
$29K
$11K
$15K
$26K
$48K
$18K
$24K
Net income
-$32.07M
-$45.64M
-$33.69M
-$25.56M
-$26.13M
-$27.02M
-$27.48M
-$25.83M
Net income attributable to common shareholders
-$32.07M
-$45.64M
-$33.69M
-$25.56M
-$26.13M
-$27.02M
-$27.48M
-$25.83M
EBITDA
-$34.81M
-$47.81M
-$34.59M
-$26.97M
-$27.63M
-$28.33M
-$28.74M
-$27.52M
Basic earnings per share
-$0.29
-$0.48
-$0.50
-$0.38
-$0.40
-$0.47
-$0.55
-$0.52
Diluted earnings per share
-$0.29
-$0.48
-$0.50
-$0.38
-$0.40
-$0.47
-$0.55
-$0.52
Recent news
Company coverage with links to the original publishers.
OXB has confirmed a manufacturing and supply partnership with Aura Biosciences to support late-stage development and commercial production of belzupacap sarotalocan (bel-sar), a virus-like drug conjugate candidate for ocular cancers. The partnership leverages OXB's FDA-approved commercial-scale facility in Durham, North Carolina, and marks OXB's entry into VDC manufacturing.
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
Aura Biosciences (AURA) has gained 22% over the past four weeks and closed at $7.65. Wall Street analysts have set a mean price target of $16.80, indicating a potential upside of 119.6%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions with a 6.5% increase over the past month. However, the article cautions that price targets alone should not be the sole basis for investment decisions.
Aura Biosciences announced inducement equity awards granted to newly appointed Chief Executive Officer and President Natalie Holles on May 19, 2026. The awards include stock options for 2.17 million shares at $7.39 exercise price, 600,118 RSUs, and 553,844 performance-based RSUs with multi-year vesting schedules. The grants align with previously disclosed terms of her offer letter and were approved by the Board in accordance with Nasdaq regulations.
Aura Biosciences, a clinical-stage biotechnology company, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, discussing their precision therapies for solid tumors.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.